Boris Orlov
Nessuna posizione attualmente
Storia della carriera di Boris Orlov
Precedenti posizioni note di Boris Orlov
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Innovalve Bio Medical Ltd.
 Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Fondatore | 01/01/2017 | - |
Lartim Medical Ltd.
 Lartim Medical Ltd. Financial ConglomeratesFinance Lartim Medical Ltd. operates as a development stage company. The company was founded by Boris Orlov in 2008 and is headquartered in Kiryat Shmona, Israel. | Direttore/Membro del Consiglio | 01/03/2008 | - |
| Fondatore | 27/10/2009 | - |
Statistiche
Distribuzione geografica
| Israele | 3 |
Posizioni
| Founder | 2 |
| Director/Board Member | 1 |
Settori
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Lartim Medical Ltd.
Lartim Medical Ltd. Financial ConglomeratesFinance Lartim Medical Ltd. operates as a development stage company. The company was founded by Boris Orlov in 2008 and is headquartered in Kiryat Shmona, Israel. | Finance |
Innovalve Bio Medical Ltd.
Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Health Technology |
- Borsa valori
- Insiders
- Boris Orlov
- Esperienza
